VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Tuesday, December 30, 2025
Stock Comparison
Gilead Sciences, Inc. vs Thomson Reuters Corporation
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Gilead Sciences, Inc.
GILD · NASDAQ Global Select Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Gilead Sciences, Inc.'s moat claims, evidence, and risks.
View GILD analysisThomson Reuters Corporation
TRI · Toronto Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Thomson Reuters Corporation's moat claims, evidence, and risks.
View TRI analysisComparison highlights
- Moat score gap: Thomson Reuters Corporation leads (84 / 100 vs 74 / 100 for Gilead Sciences, Inc.).
- Segment focus: Gilead Sciences, Inc. has 5 segments (68.5% in HIV); Thomson Reuters Corporation has 5 segments (40.1% in Legal Professionals).
- Primary market structure: Oligopoly vs Duopoly. Pricing power: Moderate vs Strong.
- Moat breadth: Gilead Sciences, Inc. has 8 moat types across 3 domains; Thomson Reuters Corporation has 4 across 3.
Primary market context
Gilead Sciences, Inc.
HIV
HIV treatment and prevention medicines (antiretroviral therapy and PrEP)
Global (U.S. and Europe are major markets)
Patients/prescribers; reimbursed by public and private payers; distributed via wholesalers and specialty pharmacies
Drug developer and marketing authorization holder
68.5%
Thomson Reuters Corporation
Legal Professionals
Legal research and legal workflow software
Global
Law firms, corporate legal departments, and governments
Subscription software + proprietary legal content
40.1%
Side-by-side metrics
Moat coverage
Shared moat types
Gilead Sciences, Inc. strengths
Thomson Reuters Corporation strengths
Segment mix
Gilead Sciences, Inc. segments
Full profile >HIV
Oligopoly
Oncology (Cell Therapy + Trodelvy)
Oligopoly
Liver Disease
Oligopoly
Veklury (Remdesivir)
Competitive
Other Products
Competitive
Thomson Reuters Corporation segments
Full profile >Legal Professionals
Duopoly
Corporates
Oligopoly
Tax & Accounting Professionals
Oligopoly
Reuters News
Oligopoly
Global Print
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.